Regulatory Exclusivity: NEW INDICATION
✉ Email this page to a colleague
Drugs with New Indication Regulatory Exclusivity
Click here to exclude patents covering these drugs from this list
Applicant | Tradename | Generic Name | NDA | Approval Date | Type | Patent No. | Patent Expiration | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | XALKORI | crizotinib | 202570 | Aug 26, 2011 | RX | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
Pf Prism Cv | XALKORI | crizotinib | 202570 | Aug 26, 2011 | RX | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
Pf Prism Cv | XALKORI | crizotinib | 202570 | Aug 26, 2011 | RX | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
Pf Prism Cv | XALKORI | crizotinib | 202570 | Aug 26, 2011 | RX | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
Pf Prism Cv | XALKORI | crizotinib | 202570 | Aug 26, 2011 | RX | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE |
>Applicant | >Tradename | >Generic Name | >NDA | >Approval Date | >Type | >Patent No. | >Patent Expiration | >Exclusivity Expiration | >Patented / Exclusive Use |